Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral,multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
Abstract
Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral,multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.
참고문헌 (13)
- Lonser RR, "von Hippel-Lindau disease", Lancet, 361, pp.2059~2067 (2003)
- Motzer RJ, "Renal-cell carcinoma", N Engl J Med, 335, pp.865~875 (1996)
- Negrier S, "Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renalcell carcinoma. Groupe Francais d'Immunotherapie", N Engl J Med, 338, pp.1272~1278 (1998)
- Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma", N Engl J Med, 356, pp.115~124 (2007)
- Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma", N Engl J Med, 356, pp.2271~2281 (2007)
- Escudier B, "Phase III trial of bevacizumab plus interferon alfa- 2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival", J Clin Oncol, 28, pp.2144~2150 (2010)
- Friedrich CA, "Von Hippel-Lindau syndrome: a pleomorphic condition", Cancer, 86(11 Suppl), pp.2478~2482 (1999)
- Jonasch E, "Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease", Ann Oncol, 22, pp.2661~2666 (2011)
- Yoo C, "The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction", Jpn J Clin Oncol, 40, pp.980~985 (2010)
- Rini BI, "Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial", Lancet, 378, pp.1931~1939 (2011)
- Zama IN, "Sunitinib rechallenge in metastatic renal cell carcinoma patients", Cancer, 116, pp.5400~5406 (2010)
- Wanebo JE, "The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease", J Neurosurg, 98, pp.82~94 (2003)
- Hammel PR, "Pancreatic involvement in von Hippel- Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau", Gastroenterology, 119, pp.1087~1095 (2000)